CoChat

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic

Open access
Li, Dongxu, Yu, Xufen, Kottur, Jithesh, Gong, Weida, Zhang, Zhao, Storey, Aaron J., Tsai, Yi-Hsuan, Uryu, Hidetaka, Shen, Yudao, Byrum, Stephanie D., Edmondson, Rick D., Mackintosh, Samuel G., Cai, Ling, Liu, Zhijie, Aggarwal, Aneel K., Tackett, Alan J., Liu, Jing, Jin, Jian, Wang, Gang Greg · 2022 · Oncogene
Cited by 57

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine methyltransferase complex, is critically involved in oncogenesis and represents an attractive onco-target. Inhibitors targeting protein-protein interactions (PPIs) between WDR5 and its binding partners, however, do not inhibit all of WDR5-mediated oncogenic functions and exert rather limited antitumor effects. Here, we report a cereblon (CRBN)-recruiting proteolysis targeting chimera (PROTAC) of WDR5, MS40, which selectively degrades WDR5 and the well-established neo-substrates of immunomodulatory drugs (IMiDs):CRBN, the Ikaros zinc finger (IKZF) transcription factors IKZF1 and IKZF3. MS40-induced WDR5 degradation caused disassociation of the MLL/KMT2A complex off chromatin, resulting in decreased H3K4me2. Transcriptomic profiling revealed that targets of both WDR5 and IMiDs:CRBN were significantly repressed by treatment of MS40. In MLL-rearranged leukemias, which exhibit IKZF1 high expression and dependency, co-suppression of WDR5 and Ikaros by MS40 is superior in suppressing oncogenesis to the WDR5 PPI inhibitor, to MS40’s non-PROTAC analog controls (MS40N1 and MS40N2, which do not bind CRBN and WDR5, respectively), and to a matched VHL-based WDR5 PROTAC (MS169, which degrades WDR5 but not Ikaros). MS40 suppressed the growth of primary leukemia patient cells in vitro and patient-derived xenografts in vivo. Thus, dual degradation of WDR5 and Ikaros is a promising anti-cancer strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-022-02340-8

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 57

Metadata

Authors
Li, D., Yu, X., Kottur, J., Gong, W., Zhang, Z., Storey, A. J., Tsai, Y.-H., Uryu, H., Shen, Y., Byrum, S. D., Edmondson, R. D., Mackintosh, S. G., Cai, L., Liu, Z., Aggarwal, A. K., Tackett, A. J., Liu, J., Jin, J., & Wang, G. G.
Venue
Oncogene
Published
2022-05-07
Volume
41
Issue
24
Pages
3328-3340
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W4229025713
Cited by
57
References
14
FWCI
3.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. https://app.cochat.ai/papers/10.1038/s41388-022-02340-8
The paper
Li, D., Yu, X., Kottur, J., Gong, W., Zhang, Z., Storey, A. J., Tsai, Y.-H., Uryu, H., Shen, Y., Byrum, S. D., Edmondson, R. D., Mackintosh, S. G., Cai, L., Liu, Z., Aggarwal, A. K., Tackett, A. J., Liu, J., Jin, J., & Wang, G. G. (2022). Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. https://doi.org/10.1038/s41388-022-02340-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.